According to a white paper released by Access to Medicine Foundation (AMF), “Pharmaceutical companies must bring a step change in their practices for stock and inventory management, improve their agility in response to shortages, and communicate information about their plans and stock data earlier and in more detail to more partners.” Strengthening the antibiotic supply chain is more than a benefit to the pharmaceutical industry—in fact, failure to do so could result in financial consequences, such as increased hospital, pharmacy and patient costs. These costs could float all the way back up to manufacturers.
